Evidence map›Paper›PMID 34988906›Full record

ArticleJournal of gastrointestinal cancer2022

Evaluation of Human Wharton's Jelly-Derived Mesenchymal Stem Cells Conditioning Medium (hWJ-MSCs-CM) or Scorpion Venom Breast Cancer Cell Line In Vitro.

Yasmen Mohamed Said, Nadia E A El-Gamel, Said A Ali, Aly Fahmy Mohamed

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yasmen Mohamed SaidThe International Center for Advanced Researches (ICTAR), Giza, Egypt.
Nadia E A El-GamelDepartment of Chemistry, Faculty of Science, Cairo University, Giza, Egypt. nadinealy@hotmail.com.ORCID http://orcid.org/0000-0002-7148-8360
Said A AliDepartment of Biophysics, Faculty of Science, Cairo University, Giza, Egypt.
Aly Fahmy MohamedThe International Center for Advanced Researches (ICTAR), Giza, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe present study aimed to evaluate the anticancer potential of Egyptian scorpion Leiurus quinquestriatus venom (ScV) or human Wharton's jelly-derived mesenchymal stem cells conditioning medium (hWJ-MSCs-CM)/CM against breast cancer (MCF-7) cell line as an alternative effective cancer biotherapy.

methodsVenom (ScV) toxicity was performed recording concentration-dependent viability % and ScV IC

resultsBoth Bax and Casp-3 showed a significant upregulation while anti-apoptotic genes were significantly downregulated. In the meantime, Casp-3 and Casp-9 protein were monitored using ELISA, and their level was less than in control. Additionally, MCF-7 apoptosis was monitored using flow cytometry recording a significant DNA accumulation in the G0-G1 and S phases in case of cell treatment with ScV or CM75% ml and 50% ml. Also, there was a significant total necrotic cells % compared with control cells, and total apoptosis under the effect of ScV or CM75% ml was significantly elevated than rest of treatment.

conclusionApoptosis induction was both dose- and time-dependent for hWJ-MSCs-CM and ScV. According to the present study and other studies, there is an ample evidence that hWJ-MSCs-CM and the venom IC

Indexed as

Breast NeoplasmsCulture Media, ConditionedMesenchymal Stem CellsScorpion VenomsWharton Jellybcl-2-Associated X ProteinCell DifferentiationFemaleHumansMCF-7 Cellsbcl-2-Associated X ProteinCulture Media, ConditionedScorpion VenomsApoptosisBreast cancerConditioning mediumLeiurus quinquestriatusMesenchymal stem cellsWharton’s jelly

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.